SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is drawing attention with its focus on regulatory compliance, notably achieving ISO 20022, and expanding strategic partnerships with platforms like Dash and NatPay to enhance its real-time payment rails. The community is actively discussing these foundational milestones and the anticipated Super App launch, largely viewing current valuations as a prime accumulation phase for a project aiming to revolutionize digital payroll and payments.

Infosys Ltd. is a digital services and consulting company, which engages in the provision of end-to-end business solutions. It operates through the following segments: Financial Services, Retail, Communication; Energy, Utilities, Resources, and Services; Manufacturing, Hi-Tech, Life Sciences, and All Other. The company was founded by Dinesh Krishnan Swamy, Senapathy Gopalakrishnan, Narayana Ramarao Nagavara Murthy, Raghavan N. S., Ashok Arora, Nandan M. Nilekani, and S. D. Shibulal on July 2, 1981 and is headquartered in Bangalore, India.

Infosys Ltd - ADR

Infosys Technologies Limited

Infosys (INFY) ADRs are trending due to extreme, unprecedented volatility and a trading halt, which market participants attributed to an "algo glitch" or data mismatch rather than fundamental news. The community is actively discussing the rapid, unexplained price surge and subsequent retracement, with some capitalizing on the swings while others express skepticism about the nature of the event. This highly unusual action for a large-cap IT services company has fueled widespread conversation regarding market mechanics.

Starfighters Space Inc

Starfighters Space Inc (FJET) is trending as a volatile new entrant in the commercial space sector, garnering attention for its unique supersonic aircraft capable of payload launches. Community discussion is polarized, with some investors seeing significant upside due to its niche, while others express strong concerns over perceived dilution from warrants and a lack of clear business updates.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending due to an ongoing, highly contentious shareholder vote regarding share authorization, which has divided investors between those anticipating growth and others concerned about dilution. Concurrently, a new strategic partnership with C Speed to deliver AI-enabled border security is generating optimism, with many viewing it as a significant step toward securing major defense and homeland security contracts. This activity, coupled with high trading volume and long-term comparisons to Palantir, highlights intense community interest in the company's future in the AI defense sector.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab (RKLB) is trending after securing its largest contract to date, an $816 million award from the Space Development Agency to build 18 Tranche 3 Tracking Layer satellites. This significant win validates Rocket Lab's position alongside major defense primes in national security space, driving strong bullish sentiment and community discussion about the company's end-to-end capabilities and future growth in the rapidly expanding space sector.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals is trending due to a recently announced special cash dividend of $0.80 per share and an anticipated strategic pivot towards emerging financial infrastructure and blockchain-based assets under new leadership. This has ignited robust community debate around the stock's 'monster runner' potential and short-squeeze dynamics, balancing speculative growth opportunities against concerns of significant dilution. Traders are actively navigating this heightened volatility, watching how this biotech-to-blockchain shift performs amid current small-cap market enthusiasm.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG is gaining significant attention, driven by strategic acquisitions from public entities like C2 Blockchain, which emphasizes its role as a Bitcoin-native digital asset within the ecosystem. The dedicated "DOG Army" community is actively discussing its unique fixed supply and superior Runes protocol, believing it's positioned to become the leading meme coin on Bitcoin. This strong conviction fuels discussions around its long-term potential and widespread adoption.

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Cytokinetics Inc

Cytokinetics is trending following the recent FDA approval of its heart disease drug MYQORZO (aficamten), a groundbreaking treatment for obstructive hypertrophic cardiomyopathy. The community is actively debating the drug's favorable REMS program compared to rivals, along with its strong Phase 3 data, which is intensifying speculation around its potential as a first-line therapy and renewed buyout prospects.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is trending due to significant volatility in its underlying asset, Super Micro Computer (SMCI), a crucial player in AI server infrastructure, driving intense 'buy the dip' activity among many investors. The community is highly engaged in discussions about the optimal entry points, balancing the potential for amplified gains from this 2x leveraged ETF against its inherent decay and dramatic price swings. Despite cautionary tales and recent downturns, a strong underlying bullish sentiment anticipates a substantial rebound fueled by future growth in the AI sector.

Ancient8 is the gaming L2 on Ethereum backed by Dragonfly, Pantera, Hashed, Coinbase Ventures and Makers Fund. Ancient8 offers a suite of Web3 gaming infrastructure tools that serve as the distribution and marketing channel for games globally.

Ancient8

A8 CRYPTO is a trending topic, primarily due to its status as a recently listed gaming token, igniting a highly polarized debate within the community. Many bulls are anticipating a significant 'alt season' rally, drawing comparisons to other tokens that experienced substantial post-listing pumps, while a vocal skeptical faction labels it a 'scam' or 'rugpull' due to concerns over token distribution and developer practices.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Allogene's Q1 Earnings In Line With Estimates, Sales Nil

Elevation Oncology downgraded as it halts lead asset on disappointing trials

Investing.com -- Wall Street cut rating on  Elevation Oncology  Inc (NASDAQ:ELEV) after the company announced it will discontinue development of its lead asset, EO-3021, due to disappointing efficacy in a Phase 1 trial. Analysts now see limited near-term catalysts, with Elevation pivoting to its HER3-targeted ADC, EO-1022, which is still in preclinical development.

Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The firm’s program is focused on patients with advanced solid tumors harboring an NRG1 fusion. The company was founded by Shawn M. Leland in 2019 and is headquartered in Boston, MA.

ELEV
Elevation Oncology Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ELEV News

ELEVElevation Oncology Inc